Lataa...
Recent advances in antimultiple myeloma drug development
Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia...
Tallennettuna:
| Julkaisussa: | Pharm Pat Anal |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4465869/ https://ncbi.nlm.nih.gov/pubmed/24998287 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/ppa.14.18 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|